News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 20, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
Clinical confirmation of the effect of Rhopressa ® on trabecular meshwork outflow facility in patients with open-angle glaucoma or ocular hypertension DURHAM, N.C. --(BUSINESS WIRE)--Aug. 15, 2018-- Aerie Pharmaceuticals , Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, August 8 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Aug. 8, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 2, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018 . Following the release, the Company will host a live
View HTML
Toggle Summary Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology
Promising Technology Platform to Potentially Deliver Therapies to Treat a Broad Spectrum of Ophthalmic Diseases DURHAM, NC & EXTON, Pa. --(BUSINESS WIRE)--Aug. 1, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Deerfield’s Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 16, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML